"Doctor, if it were you, which would you choose?": Navigating personal preference questions in anti-amyloid immunotherapy selection
{{output}}
The approval of lecanemab and donanemab represents a watershed moment in Alzheimer Disease (AD) treatment, yet clinicians face a novel challenge: guiding patients through treatment selection when head-to-head comparative data are absent. When confronted with t... ...
